Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin, Lenalidomide, and Daratumumab in Multiple Myeloma
NCT04892264Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Jun 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose up to 28 days and Complete Response Rate. Started Jun 2021; status: terminated.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04892264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892264.